In patients with early onset preeclampsia does the addition of pravastatin compared to current practice (historical cohort from 2006) lead to a reduction in symptoms and signs and prolongation of pregnancy?

The Mercy Hospital for Women0 个研究点目标入组 12 人开始时间: 2013年3月6日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•We will include women with a singleton pregnancy between 23+0 weeks to 32+6 weeks, diagnosed with preeclampsia as per the Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) guidelines, confined to proteinuric preeclampsia between 0.5 – 1.5g per 24hour period at recruitment. This is because it is likely those with other organ involvement, or severe fetal growth restriction, are likely to be offered delivery very soon and it is unlikely there will be an adequate window of opportunity for the pravastatin to have effect.
•Further inclusion criteria:
•- the admitting clinicians have already made the decision not to immediately deliver.
•- no major anomalies on morphology ultrasound
•- Patient is capable of understanding the study and their involvement in it.

•- The presence of growth restriction (<10th percentile) at the time of involvement
•- Obvious organ involvement other than renal at the time of recruitment
•- Current use of statins
•- Contraindication to statins (liver failure, muscular disease, hypersensitivity, current use of erythromycin)
•Note: these are only exclusion criteria at the time of recruitment. If these complications develop, patients will remain in the study.

发起方

The Mercy Hospital for Women